Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
October 21, 2015 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of...
Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
September 09, 2014 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2014
June 30, 2014 14:05 ET
|
Elite Pharmaceuticals, Inc.
Revenues Increase by 35%, Product Development Accelerating
Conference Call Scheduled for Tuesday, July 1 at 12:00 PM EDT
NORTHVALE, N.J., June 30, 2014 (GLOBE NEWSWIRE) -- Elite...
Elite Pharmaceuticals Announces Results of 2014 Annual Meeting of Shareholders
May 23, 2014 11:08 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 23, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) today announced the voting results of matters considered during the...
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally
March 10, 2014 07:46 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 10, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the expansion of intellectual property protection surrounding...